Premium
Secukinumab treatment of plaque psoriasis shows early improvement in DLQI response – results of a phase II regimen‐finding trial
Author(s) -
Augustin M.,
Abeysinghe S.,
Mallya U.,
Qureshi A.,
Roskell N.,
McBride D.,
Papavassillis C.,
Gelfand J.
Publication year - 2016
Publication title -
journal of the european academy of dermatology and venereology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.655
H-Index - 107
eISSN - 1468-3083
pISSN - 0926-9959
DOI - 10.1111/jdv.13478
Subject(s) - medicine , secukinumab , placebo , dermatology life quality index , regimen , psoriasis , psoriasis area and severity index , quality of life (healthcare) , randomized controlled trial , surgery , dermatology , pathology , psoriatic arthritis , alternative medicine , nursing
Background The social stigma and chronicity of psoriasis significantly affect health‐related quality of life (HRQoL). Objective We examined the effect of three regimens of secukinumab on HRQoL in moderate to severe psoriasis patients. Methods Twelve‐week data from a phase II, randomized, double‐blind, placebo‐controlled, regimen‐finding study evaluated HRQoL, measured by the Dermatology Life Quality Index (DLQI). Secukinumab or placebo was administered subcutaneously in three treatment regimens: single (baseline only), monthly (baseline, weeks 4, 8) and early (baseline, weeks 1, 2, 4). Differences among regimens were assessed with logistic regression models and Fisher's exact test. Results Patients ( n = 404) were randomized to single (baseline) treatment regimen, n = 66; monthly, (baseline, weeks 4 and 8), n = 138; early, (baseline, weeks 1, 2, 4), n = 133; and placebo, n = 67. DLQI response was significantly higher in early, monthly and single regimens than in placebo regimen (40.8%, 33.6% and 13.1% vs. 1.6%, respectively; P < 0.001 for all). Conclusion Moderate to severe psoriasis patients receiving monthly and early treatment with secukinumab demonstrated improved HRQoL compared with placebo.